Experienced in Systemic Sclerosis (SSc)

Dr. Michele L. Donato

Oncology | Hematology
HackenSack Meridian health
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 
Clinical Trials:Currently Recruiting for 1 Trial
28 Years of Experience

Experienced in Systemic Sclerosis (SSc)
HackenSack Meridian health
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michele Donato is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Donato has been practicing medicine for over 28 years and is rated as an Experienced provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Colonoscopy.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Systemic Sclerosis (SSc).

Graduate Institution
McGill University
Specialties
Oncology
Hematology
Licenses
Internal Medicine in NJ
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Texas MD Anderson Cancer Center
Hospital Affiliations
Ocean Medical Center
Hackensack University Medical Center
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, Hackensack, NJ 7601.
Call: 551-996-8297
Other Locations
HMH - John Theurer Cancer Center - Neptune
19 Davis Avenue, Floor 2, Neptune, NJ 7753.
Call: 732-897-3530

Additional Areas of Focus

Dr. Donato has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


15 Clinical Trials

Phase 2/3 Trial of Autologous Hybrid TREG/Th2 (RAPA-501) T Stem Cell Therapy for Amyotrophic Lateral Sclerosis
Phase 2/3 Trial of Autologous Hybrid TREG/Th2 (RAPA-501) T Stem Cell Therapy for Amyotrophic Lateral Sclerosis
Enrollment Status: Recruiting
Publish Date: June 18, 2025
Intervention Type: Biological
Study Drug: RAPA-501 Autologous Treg/Thelper 2 Cells
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 30, 2025
Intervention Type: Drug
Study Drug: Zelenoleucel
Study Phase: Phase 2
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: Bortezomib
Study Phase: Phase 3
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 1
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Biological
Study Phase: Phase 1
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
Enrollment Status: Terminated
Publish Date: November 28, 2023
Intervention Type: Drug
Study Drugs: Melphalan, Bortezomib
Study Phase: Phase 2
Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection
Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection
Enrollment Status: Terminated
Publish Date: October 10, 2023
Intervention Type: Biological, Other
Study Drug: Anti-COVID-19 Plasma
Study Phase: Phase 2
Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection
Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Biological
Study Drug: Anti-COVID-19 Plasma
Study Phase: Phase 2
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drugs: Fludarabine, Busulfan
Study Phase: Phase 3
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Enrollment Status: Unknown
Publish Date: February 16, 2023
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19
Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19
Enrollment Status: No_longer_available
Publish Date: October 12, 2022
Intervention Type: Biological
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS
Phase I/Phase II Trial of Allogeneic Hybrid TREG/Th2 Cell (RAPA-501-ALLO) Therapy for COVID-19-Related ARDS
Enrollment Status: Terminated
Publish Date: November 11, 2021
Intervention Type: Other, Biological
Study Drug: RAPA-501-Allo off-the-shelf Therapy of COVID-19
Study Phase: Phase 1/Phase 2
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Genetic, Other
Study Phase: Phase 3
View 14 Less Clinical Trials

64 Total Publications

Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia.
Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia.
Journal: Transplantation and cellular therapy
Published: May 09, 2025
View All 64 Publications
Similar Doctors
Advanced in Systemic Sclerosis (SSc)
Dr. Kevin M. Troy
Hematology
Advanced in Systemic Sclerosis (SSc)
Dr. Kevin M. Troy
Hematology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (8.4 miles away)
212-241-4812
Languages Spoken:
English
See accepted insurances

Kevin Troy is a Hematologist in New York, New York. Dr. Troy is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Factor 11 Deficiency, Thrombocytopenia, Idiopathic Neutropenia, Shwartzman Phenomenon, and Bone Marrow Aspiration.

Experienced in Systemic Sclerosis (SSc)
Dr. Roni Shouval
Hematology | Transplant Surgery
Experienced in Systemic Sclerosis (SSc)
Dr. Roni Shouval
Hematology | Transplant Surgery

Mskcc Clinical Practice Plan

1275 York Ave, 
New York, NY 
 (9.8 miles away)
212-639-2000
Experience:
17+ years
Languages Spoken:
English

Roni Shouval is a Hematologist and a Transplant Surgeon in New York, New York. Dr. Shouval has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Bone Marrow Transplant, and Bone Graft.

Experienced in Systemic Sclerosis (SSc)
Dr. Mary K. Leung
Hematology | Oncology
Experienced in Systemic Sclerosis (SSc)
Dr. Mary K. Leung
Hematology | Oncology

Mount Sinai School Of Medicine

242 Merrick Rd, 
Rockville Centre, NY 
 (26.5 miles away)
516-536-1455
Languages Spoken:
English
See accepted insurances

Mary Leung is a Hematologist and an Oncologist in Rockville Centre, New York. Dr. Leung is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Anemia, Angiosarcoma, Paget Disease of the Breast, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

VIEW MORE SYSTEMIC SCLEROSIS (SSC) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Donato's expertise for a condition
ConditionClose
  • Elite
  • Bone Marrow Transplant
    Dr. Donato is
    Elite
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Multiple Myeloma
    Dr. Donato is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Distinguished
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Donato is
    Distinguished
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Donato is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Donato is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Donato is
    Distinguished
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adult T-Cell Leukemia
    Dr. Donato is
    Distinguished
    . Learn about Adult T-Cell Leukemia.
    See more Adult T-Cell Leukemia experts
  • Childhood Acute Myeloid Leukemia
    Dr. Donato is
    Distinguished
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
View All 12 Distinguished Conditions
  • Advanced
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Donato is
    Advanced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Aplastic Anemia
    Dr. Donato is
    Advanced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
  • B-Cell Lymphoma
    Dr. Donato is
    Advanced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Chronic Graft Versus Host Disease (cGvHD)
    Dr. Donato is
    Advanced
    . Learn about Chronic Graft Versus Host Disease (cGvHD).
    See more Chronic Graft Versus Host Disease (cGvHD) experts
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Donato is
    Advanced
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Chronic Myelogenous Leukemia (CML)
    Dr. Donato is
    Advanced
    . Learn about Chronic Myelogenous Leukemia (CML).
    See more Chronic Myelogenous Leukemia (CML) experts
View All 23 Advanced Conditions
  • Experienced
  • Acute Erythroid Leukemia (AEL)
    Dr. Donato is
    Experienced
    . Learn about Acute Erythroid Leukemia (AEL).
    See more Acute Erythroid Leukemia (AEL) experts
  • Acute Myelomonocytic Leukemia
    Dr. Donato is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Acute Promyelocytic Leukemia
    Dr. Donato is
    Experienced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Agranulocytosis
    Dr. Donato is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anaplastic Large Cell Lymphoma
    Dr. Donato is
    Experienced
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Angioimmunoblastic T-cell Lymphoma
    Dr. Donato is
    Experienced
    . Learn about Angioimmunoblastic T-cell Lymphoma.
    See more Angioimmunoblastic T-cell Lymphoma experts
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.